Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By <i>TP53</i> and <i>IDH1/2</i> Mutation: Results from the AML Real World Evidence (ARC) InitiativeOfir Wolach, Aaron D. Goldberg, Joshua F. Zeidner et al.|Blood|2022Cited by 2
Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review studyJacqueline S. Garcia, Aaron D. Goldberg, P Desai et al.|Leukemia & lymphoma/Leukemia and lymphoma|2026Cited by 0